Tumormarkører ved epitelial ovariecancer

Morten H Sparholt; Estrid Høgdall; Claus K Høgdall

Tumormarkører ved epitelial ovariecancer

Translated title of the contribution: [Tumour markers in epithelial ovarian cancer]

Morten H Sparholt, Estrid Høgdall, Claus K Høgdall

Department of Pathology

2 Citations (Scopus)

Abstract

In October 2007, the Danish government and regions made an agreement comprising acute treatment of ovarian cancer (OC) patients. The acute OC-package includes the tumour marker cancer antigen 125 (CA125) as an essential factor. This marker is yet not optimal due to too low sensitivity/specificity. There is therefore a need for new or supplementary markers to improve the treatment. As the agreement will be influencing all diagnostic procedures, there is, furthermore, a need for information about OC and tumor markers. In this article we review the literature and illustrate future challenges and opportunities in OC marker diagnostics.

Translated title of the contribution	[Tumour markers in epithelial ovarian cancer]
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	171
Issue number	48
Pages (from-to)	3505-9
Number of pages	5
Publication status	Published - 23 Nov 2009

Cite this

@article{80c56d3512644913a3ae416f622bb1a1,

title = "Tumormark{\o}rer ved epitelial ovariecancer",

abstract = "In October 2007, the Danish government and regions made an agreement comprising acute treatment of ovarian cancer (OC) patients. The acute OC-package includes the tumour marker cancer antigen 125 (CA125) as an essential factor. This marker is yet not optimal due to too low sensitivity/specificity. There is therefore a need for new or supplementary markers to improve the treatment. As the agreement will be influencing all diagnostic procedures, there is, furthermore, a need for information about OC and tumor markers. In this article we review the literature and illustrate future challenges and opportunities in OC marker diagnostics.",

author = "Sparholt, \{Morten H\} and Estrid H{\o}gdall and H{\o}gdall, \{Claus K\}",

year = "2009",

month = nov,

day = "23",

language = "Dansk",

volume = "171",

pages = "3505--9",

journal = "Ugeskrift for Laeger",

issn = "1399-4174",

publisher = "Almindelige Danske Laegeforening",

number = "48",

}

TY - JOUR

T1 - Tumormarkører ved epitelial ovariecancer

AU - Sparholt, Morten H

AU - Høgdall, Estrid

AU - Høgdall, Claus K

PY - 2009/11/23

Y1 - 2009/11/23

N2 - In October 2007, the Danish government and regions made an agreement comprising acute treatment of ovarian cancer (OC) patients. The acute OC-package includes the tumour marker cancer antigen 125 (CA125) as an essential factor. This marker is yet not optimal due to too low sensitivity/specificity. There is therefore a need for new or supplementary markers to improve the treatment. As the agreement will be influencing all diagnostic procedures, there is, furthermore, a need for information about OC and tumor markers. In this article we review the literature and illustrate future challenges and opportunities in OC marker diagnostics.

AB - In October 2007, the Danish government and regions made an agreement comprising acute treatment of ovarian cancer (OC) patients. The acute OC-package includes the tumour marker cancer antigen 125 (CA125) as an essential factor. This marker is yet not optimal due to too low sensitivity/specificity. There is therefore a need for new or supplementary markers to improve the treatment. As the agreement will be influencing all diagnostic procedures, there is, furthermore, a need for information about OC and tumor markers. In this article we review the literature and illustrate future challenges and opportunities in OC marker diagnostics.

UR - https://www.scopus.com/pages/publications/77954916315

M3 - Tidsskriftartikel

C2 - 19944049

SN - 1399-4174

VL - 171

SP - 3505

EP - 3509

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 48

ER -

Tumormarkører ved epitelial ovariecancer

Abstract

Other files and links

Fingerprint

Cite this